Rajaratnam Misses Court After Surgery, No Jury Deliberations Today

May 3 2011 | 4:08am ET

Medical matters dominated the sixth day of deliberations at the Raj Rajaratnam insider-trading trial, which ended as the five previous days ended: without a verdict.

Rajaratnam himself wasn't in the courtroom: The Galleon Group chief was excused by U.S. District Judge Richard Holwell, having had emergency surgery to treat a bacterial infection of his foot on Sunday.

"It is hoped that he will be recovered sufficiently to return to the courthouse this week," Rajaratnam's lawyer, John Dowd, said in a statement. "The court has approved this absence."

Holwell echoed that statement before dismissing the jury, telling them that Rajaratnam "couldn't be here and I've excused him for a good reason."

None of them will be there today: A juror's medical procedure has pre-empted the deliberations, which will enter their seventh day tomorrow. The delay came after the jurors sent Holwell a note yesterday—their first communication with the court since Wednesday. The note, dealing with the medical issue, was not released, but Holwell's letter to the jury was.

"No juror should feel any time pressure whatsoever," he wrote. "The jury will have all the time it needs to reach its verdict."

As for Rajaratnam, his spokesman, Jim McCarthy, said he understood that Rajaratnam would not have to be in court tomorrow. He added that he believed a verdict could be handed down whether or not Rajaratnam is present.

If Rajaratnam is convicted, he faces decades in prison.


In Depth

Malik: The Science of Deal Sourcing 201

Aug 27 2015 | 5:35pm ET

Deal sourcing is understandably a hot topic among private equity firms because it...

Lifestyle

Rolling Art Advisors Marketing Collectible Car Fund As Uncorrelated Alternative

Aug 27 2015 | 6:47pm ET

A new fund is trying to provide investors with greater access to an emerging asset...

Guest Contributor

FATCA for Hedge Funds: Eight Common Pitfalls

Sep 1 2015 | 10:56am ET

FATCA is now a way of life for those in the financial industry and most professionals...

 

Editor's Note